NEW YORK (GenomeWeb) – Roka Bioscience said in its Form 10-Q this week that it exercised an option to reduce the royalty rate it pays to Hologic. As a result, Roka paid $8 million and issued 865,063 shares of its common stock to Hologic subsequent to the closing of Roka's initial public offering last month. The option was exercisable if Roka raised less than $55 million in net proceeds from the IPO. Net proceeds from the offering were about $53.4 million, Roka said in its SEC document.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.